Carboxymethylcellulose Sodium

drug
On this page

Also known as BlandlaxCarmellose sodiumCellufreshCelluviscCmc daicel 2450Daicel 2450Denvercel ph 2008aE 466E 468E-466Gppe pasteIns no.466Ins-466OrabaseSodium carboxymethyl celluloseSodium carboxymethylcelluloseSodium cellulose glycolateSodium cmc

Summary

Carboxymethylcellulose Sodium (CHEMBL2109001) is a phase-3 clinical-stage unknown; indicated across 4 conditions including dry eye syndrome and refractive error.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Unknown
  • Indications: 4 conditions
  • Clinical trials: 6

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL2109001
NameCarboxymethylcellulose Sodium
TypeUnknown
Max phase3

Also known as: Blandlax, Carboxymethylcellulose sodium, Carmellose sodium, Cellufresh, Celluvisc, Cmc daicel 2450, Daicel 2450, Denvercel ph 2008a, E 466, E 468, E-466, Gppe paste

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
dry eye syndrome3MONDO:0006733EFO:1000906
refractive error2MONDO:0004892HP:0000539
viral conjunctivitis2MONDO:0043541EFO:0008571

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 6.

Phase distribution

PhaseTrials
PHASE42
Not specified2
PHASE2/PHASE31
PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00809198PHASE4COMPLETEDKynex Versus Refresh Plus Study in Subject With Dry Eye
NCT02028754PHASE4COMPLETEDA Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms
NCT00691197PHASE2/PHASE3COMPLETEDSafety and Acceptability of Using a Rewetting Drop With Contact Lens Wear
NCT03418727PHASE2COMPLETEDDry Eye Disease Study With Brimonidine
NCT01544842Not specifiedTERMINATEDTacrolimus Ointment in Oral Lichen Planus
NCT02395952Not specifiedWITHDRAWNHealing of Persistent Epithelial Defects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).